WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317355

CAS#: 28395-03-1

Description: Bumetanide is a loop diuretic of the sulfamyl category to treat heart failure. It is often used in people in whom high doses of furosemide are ineffective. It is marketed by Hoffmann-La Roche. The main difference between the two substances is in bioavailability and pharmacodynamic potency. Furosemide is incompletely absorbed in the intestine (60%), and there are substantial inter- and intraindividual differences in bioavailability (range 10-90%). Bumetanide is almost completely absorbed (80%), and the absorption is not altered when it is taken with food. It is said to be a more predictable diuretic, meaning that the predictable absorption is reflected in a more predictable effect.

Chemical Structure

CAS# 28395-03-1

Theoretical Analysis

MedKoo Cat#: 317355
Name: Bumetanide
CAS#: 28395-03-1
Chemical Formula: C17H20N2O5S
Exact Mass: 364.10929
Molecular Weight: 364.4161
Elemental Analysis: C, 56.03; H, 5.53; N, 7.69; O, 21.95; S, 8.80

Size Price Shipping out time Quantity
10mg USD 60 2 Weeks
25mg USD 65 2 Weeks
50mg USD 70 2 Weeks
100mg USD 90 2 Weeks
200mg USD 120 2 Weeks
500mg USD 190 2 Weeks
1g USD 350 2 Weeks
2g USD 550 2 Weeks
5g USD 1050 2 Weeks
10g USD 1650 2 Weeks
20g USD 2650 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-02-25. Prices are subject to change without notice.

Bumetanide, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Synonym: Bumetanide, Trade names: Bumex or Burinex; PF 1593, PF-1593, PF1593

IUPAC/Chemical Name: 3-(butylamino)-4-phenoxy-5-sulfamoylbenzoic acid


InChi Code: InChI=1S/C17H20N2O5S/c1-2-3-9-19-14-10-12(17(20)21)11-15(25(18,22)23)16(14)24-13-7-5-4-6-8-13/h4-8,10-11,19H,2-3,9H2,1H3,(H,20,21)(H2,18,22,23)


Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:

Handling Instructions:

Preparing Stock Solutions

The following data is based on the product molecular weight 364.4161 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Mitsui R, Hashitani H. Mechanisms underlying spontaneous constrictions of
postcapillary venules in the rat stomach. Pflugers Arch. 2015 Nov 4. [Epub ahead
of print] PubMed PMID: 26530829.

2: Krueger D, Michel K, Zeller F, Demir IE, Ceyhan GO, Slotta-Huspenina J,
Schemann M. Neural influences on human intestinal epithelium in vitro. J Physiol.
2015 Nov 2. doi: 10.1113/JP271493. [Epub ahead of print] PubMed PMID: 26527433.

3: Pressler RM, Boylan GB, Marlow N, de Vries LS, Blennow M, Chiron C, Cross JH,
Hallberg B, Hellström-Westas L, Jullien V, Mangum B, Murphy B, Murray D, Pons G,
Rennie J, Toet MC, Zohar S; NEMO consortium (NEonatal seizure treatment with
Medication Off-patent). Bumetanide for neonatal seizures-back from the cotside.
Nat Rev Neurol. 2015 Nov 3. doi: 10.1038/nrneurol.2015.116. [Epub ahead of print]
PubMed PMID: 26526530.